PeptidePedia The community reference

Number needed to treat: difference between revisions

Diff·revision 14 → 15·05:45, 17 Jun 2025

Difference between revision 14 and revision 15 of Number needed to treat. 7 lines changed; the page grew by 867 bytes.

Revision 14 — 09:51, 20 May 2025
ArchiveBot (talk)
bot: expand PMID to full citation
3,631 bytes ±0
Revision 15 — 05:45, 17 Jun 2025
StudentSindhu (talk)
expand §Number needed to harm
4,498 bytes +867
30Presenting the two side by side is more informative than either alone, and it makes explicit that the outcomes being traded are of different kinds: a cardiovascular event and a discontinuation are not commensurable, and no arithmetic makes them so.{{r|altman1998}}30Presenting the two side by side is more informative than either alone, and it makes explicit that the outcomes being traded are of different kinds: a cardiovascular event and a discontinuation are not commensurable, and no arithmetic makes them so.{{r|altman1998}}
3131
+32== Limitations ==
+33The measure applies to the population studied. Baseline risk drives it, so a number needed to treat computed in an enriched high-risk trial population does not transfer to a lower-risk group; the relative effect transfers more readily than the absolute one.{{r|laupacis1988}}
+34
+35It also assumes a binary outcome. For a continuous endpoint such as weight change, a number needed to treat requires a threshold — for example, the number needed to treat for one additional person to lose 10% of body weight — and the choice of threshold changes the number.{{r|altman1998}} Where the threshold is not pre-specified, the resulting figure is a post hoc construction.{{r|ich_e9}}
+36
32== References ==37== References ==
33{{reflist}}38{{reflist}}
35<ref name="altman1998">Altman DG. "Confidence intervals for the number needed to treat." ''BMJ'' 317(7168):1309–1312 (1998). PMID 9804726.</ref>40<ref name="altman1998">Altman DG. "Confidence intervals for the number needed to treat." ''BMJ'' 317(7168):1309–1312 (1998). PMID 9804726.</ref>
36<ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref>41<ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref>
+42<ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref>
3743
38== See also ==44== See also ==
41* [[SELECT trial]]47* [[SELECT trial]]
42* [[Surrogate endpoint]]48* [[Surrogate endpoint]]
+49* [[Randomised controlled trial]]
4350
44{{DEFAULTSORT:Number needed to treat}}51{{DEFAULTSORT:Number needed to treat}}